pcNewsWire – Helix BioPharma Corp. (TSX/FSE: HBP) has closed a private placement of units at $1.20 per unit for gross proceeds of approximately CDN $3,028,800.
ACM Alpha Management Consulting Est. provided financial advisory services to Helix in connection with the private placement.
Net proceeds of the private placement will be used for working capital and research and development activities.
HELIX BIOPHARMA CORP. CLOSES PRIVATE PLACEMENT
(Toronto, Ontario) – Helix BioPharma Corp. (TSX:HBP)(FRANKFURT:HBP) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced it has closed a private placement financing for gross proceeds of approximately CAD3,028,800.
The terms of the placement are for the purchase of units at $1.20 per unit. Each unit is comprised of one common share and one common share purchase warrant. Each common share purchase warrant will entitle the holder to purchase one common share at an exercise price of $1.50 and have an expiry of five years from the date of issuance. Helix intends to use the net proceeds of the private placement for working capital and research and development activities.
ACM Alpha Management Consulting Est. provided financial advisory services to Helix in connection with the private placement. To date in the 2017 calendar year, the Company has raised in aggregate approximately CAD5,000,000 in financing.
About Helix BioPharma Corp.
Helix BioPharma Corp. is an immuno-oncology company specializing in the field of cancer therapy. The company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix’s product development initiatives include its novel L-DOS47 new drug candidate. Helix is currently listed on the TSX and FSE under the symbol “HBP”.
Helix BioPharma Corp.
21 St. Clair Avenue East, Suite 1100
Toronto, Ontario, M4T 1L9
Tel: 416 925-3232